Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

The substantial burden of colorectal cancer and increasing trend in young adults highlight
the importance of lifestyle modification as a complement to screening for colorectal cancer …

The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1)
targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor …

Reversing the dysfunctional T cell state that arises in cancer and chronic viral infections is
the focus of therapeutic interventions; however, current therapies are effective in only some …

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30%
of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led …

Recent studies have demonstrated the potential of natural killer (NK) cells in immunotherapy
to treat multiple types of cancer. NK cells are innate lymphoid cells that play essential roles …

It is generally accepted that metabolism is able to shape the immune response. Only
recently we are gaining awareness that the metabolic crosstalk between different tumor …

Co-inhibitory receptors are important regulators of T-cell function that define the balance
between tolerance and autoimmunity. The immune regulatory function of co-inhibitory …

LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. High LAG3 and
FGL1 expression boosts tumor growth by inhibiting the immune microenvironment. This …

Although chimeric antigen receptor (CAR) T cells have demonstrated signs of antitumor
activity against glioblastoma (GBM), tumor heterogeneity remains a critical challenge. To …